Targeting Type VII/ESX Secretion Systems for Development of Novel Antimycobacterial Drugs

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|20|27|4346-4356

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.20, Iss.27, 2014-08, pp. : 4346-4356

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Review of Antimycobacterial Drugs in Development

By  

Mini Reviews in Medicinal Chemistry, Vol. 12, Iss. 13, 2012-11 ,pp. : 1404-1418

Bentham Science Publishers

Access to resources Recommend Favorite

Novel drugs targeting the cell cycle

By Webster K.R.   Kimball S.D.  

Expert Opinion on Emerging Drugs, Vol. 5, Iss. 1, 2000-02 ,pp. : 45-59

Informa Healthcare

Access to resources Recommend Favorite

Targeting Bacterial Secretion Systems: Benefits of Disarmament in the Microcosm

By  

Infectious Disorders - Drug Targets (Formerly Current Drug Targets - Infectious Disorders), Vol. 7, Iss. 1, 2007-03 ,pp. : 19-27

Bentham Science Publishers

Access to resources Recommend Favorite

DFT Based QSAR/QSPR Models in the Development of Novel Anti-tuberculosis Drugs Targeting Mycobacterium tuberculosis

By  

Current Pharmaceutical Design, Vol. 20, Iss. 27, 2014-08 ,pp. : 4455-4473

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting Trypanosoma cruzi Platelet-activating Factor Receptors: Scope for the Development of Novel Drugs to Treat Chagas Disease

By  

Mini Reviews in Medicinal Chemistry, Vol. 13, Iss. 7, 2013-01 ,pp. : 997-1004

Bentham Science Publishers

Access to resources Recommend Favorite